Recent Transactions

29-Nov-24
Pending
$320 million (AUD value)
Australia flag
Target: 

Pacific Smiles Group

Australia flag
Acquiror: 
Genesis Capital

Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover

13-Nov-24
Pending
Undisclosed
Germany flag
Target: 

Centogene GmbH

Italy flag
Acquiror: 
Charme Capital Partners

Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of  pharmaceutical solutions and diagnostic tests for rare diseases

13-Aug-24
Undisclosed
Spain flag
Target: 

U.S. Operations of NextStream

United States flag
Acquiror: 
RadiusDC

Advised RadiusDC, a national owner and operator of highly-connected, urban-located data centers, on the acquistion of a series of entities comprising the U.S. operations of NextStream, a data center operator in Latin America owned by Actis

01-Jul-24
Undisclosed
United States flag
Target: 

Medical Review Institute of America

United States flag
Acquiror: 
Parthenon Capital

Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital

08-May-24
$800 million
United States flag
Target: 

U.S. Acute Care Solutions

flag not available

Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes

20-Feb-24
Pending
$185 million
Australia flag
Target: 

myHomecare Group

Australia flag
Acquiror: 
Australian Unity

Advising Australian Unity on its acquisition of myHomecare Group

21-Dec-23
Undisclosed
Australia flag
Target: 

Exit of Homesafe Equity Release Joint Venture

Australia flag
Acquiror: 
Athy Pty Ltd

Adviser to Bendigo and Adelaide Bank on the exit of its investment in the Homesafe Equity Release Joint Venture

04-Oct-23
$610 million
United States flag
Target: 

Lucky Bucks, LLC

flag not available

Advised the Term Loan Ad Hoc Group to Lucky Bucks, one of the largest Class B coin operated amusement machine (“COAM”) route operators in Georgia, on Lucky Bucks’ financial restructuring and chapter 11 process

27-Sep-23
Undisclosed
United States flag
Target: 

Slayback Pharma LLC

United States flag
Acquiror: 
Azurity Pharmaceuticals

Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products

18-Sep-23
Pending
Undisclosed
France flag
Target: 

Central nervous system (CNS) portfolio from Sanofi

United Kingdom flag
Acquiror: 
Pharmanovia

Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company

10-Aug-23
Undisclosed
United Kingdom flag
Target: 

Clinigen Ltd’s portfolio of Established Medicines

United Kingdom flag
Acquiror: 
CNX Therapeutics

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

08-Aug-23
Pending
Undisclosed
Spain flag
Target: 

Farmalider Group

Spain flag
Acquiror: 
MCH

Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH

07-Jul-23
Pending
$439 million
Australia flag
Target: 

Australian Unity Diversified Property Fund

Australia flag
Acquiror: 
Cromwell Direct Property Fund

Advising Australian Unity Property Limited, as the responsible entity of the Australian Unity Diversified Property Fund, on Australian Unity Diversified Property Fund’s merger with Cromwell Direct Property Fund

01-Jun-23
Pending
Undisclosed
United States flag
Target: 

Interest in Joint Venture with CarepathRx Health System Solutions

United States flag
Acquiror: 
The Cigna Group

Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary

25-Apr-23
Pending
Undisclosed
United Kingdom flag
Target: 

Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®

United Kingdom flag
Acquiror: 
Advanz Pharma (UK)

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

20-Mar-23
Pending
Undisclosed
Target: 

Clinigen Ltd’s Lamda Laboratories

Germany flag
Acquiror: 
Adragos Pharma

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

10-Feb-23
Pending
$415 million
United States flag
Target: 

Gaming Services Division of Global Payments

United States flag
Acquiror: 
Parthenon Capital

Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm

23-Jan-23
Pending
$200 million
United Kingdom flag
Target: 

Clinigen Ltd’s Proleukin

United States flag
Acquiror: 
Iovance Biotherapeutics

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

28-Dec-22
Pending
Undisclosed
Japan flag
Target: 

Eisai Distribution Co., Ltd.

Japan flag
Acquiror: 
Yasuda Logistics Corporation

Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.

24-Nov-22
Pending
Undisclosed
Target: 

Kyowa Kirin International’s established medicines business

Germany flag
Acquiror: 
Grünenthal

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

19-Aug-22
$2.2 billion
United States flag
Target: 

GI Alliance

United States flag
Acquiror: 
Apollo Hybrid Value Fund

Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital

28-Mar-22
Pending
~$1.4 billion
United Kingdom flag
Target: 

Theramex

United States flag
Acquiror: 
Carlyle and PAI Partners

Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners

28-Mar-22
Pending
$105 million
United Kingdom flag
Target: 

Acacia Pharma Group plc

United States flag
Acquiror: 
Eagle Pharmaceuticals, Inc.

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

01-Feb-22
Undisclosed
United States flag
Target: 

Alteon Health

United States flag
Acquiror: 
U.S. Acute Care Solutions

Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions

Pages

show all